Prostate CancerFamily Members
The decision to watch and wait was right for my dad and for our family, and being able to talk about all the options with the doctor and primary nurse helped us make the right decision.
Patient StoriesProstate CancerProton TherapySurvivorship
By Bill Sneddon
Faced with a late-in-life diagnosis of prostate cancer, Bill Sneddon describes his positive experience with Proton therapy, the emerging alternative treatment to standard x-ray radiation.
Cancer ScreeningProstate Cancer
You know Ben Stiller as the comedic actor who made you laugh in “There’s Something About Mary,” “Zoolander,” and “Meet the Parents,” but this legend of the silver screen credits a PSA screening for saving his life.
FDA Approvals, News & UpdatesNewsworthyProstate Cancer
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer.
Patient StoriesProstate Cancer
A doctor’s mistake left Richard Churchill reeling, but during treatment for prostate cancer he found solace in nature and in many new relationships with patients, caregivers, and family members.
Oncology navigator Frank dela Rama lists the screening tools available now for diagnosing prostate cancer.
Frank dela Rama talks about some of the stigma and miscommunication surrounding prostate cancer screening and the need for clarity.
Patient AdvocacyPatient StoriesProstate Cancer
Dennis Golden was an active, fit, 70-year-old when he learned he had prostate cancer. He was surprised to discover that few men know the warning signs and how potentially serious it can be. In response, he formed the National Prostate Cancer Awareness Foundation to educate men about this disease.
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
The Combination of Cabometyx plus Tecentriq Improves Outcomes in Patients with Advanced Prostate Cancer
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Results 1 - 17 of 17